- Conditions
- Alzheimer Disease
- Interventions
- Pepinemab, Placebo
- Drug
- Lead sponsor
- Vaccinex Inc.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 14
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cognitive Deficits, Proprioceptive Disorders
- Interventions
- Sensory Organization Test, Biomarkers, Conners' Adult ADHD Rating Scale (CAARS), Depression Scale, Cognitive Assessment
- Other · Genetic
- Lead sponsor
- New York Institute of Technology
- Other
- Eligibility
- 40 Years to 80 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Old Westbury, New York
- Conditions
- Chronic Traumatic Encephalopathy (CTE), Alzheimer Disease, Alzheimer Disease and Related Dementias (ADRD), Brain Injuries, Traumatic
- Interventions
- Not listed
- Lead sponsor
- Boston University
- Other
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 2 more
- Conditions
- Mild Cognitive Impairment, Normal Aging
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 21 Years to 86 Years
- Enrollment
- 22,720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- Disclose amyloid, tau results, Follow-up Assessments
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 45 Years to 89 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer Disease
- Interventions
- 18F-MK-6240, Lumbar Puncture (optional)
- Drug · Procedure
- Lead sponsor
- Patrick Lao
- Other
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimers Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 80,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
- Interventions
- Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Biological
- Lead sponsor
- Steven E Arnold, MD
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 40 Years to 64 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 18
- States / cities
- Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Alzheimer Disease
- Interventions
- LY3372689, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 35
- States / cities
- Canoga Park, California • Fresno, California • Irvine, California + 30 more
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment, Frontotemporal Dementia
- Interventions
- COGNISION™ System
- Device
- Lead sponsor
- Neuronetrix, Inc.
- Industry
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- West Palm Beach, Florida • Lexington, Kentucky • Louisville, Kentucky + 4 more
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Angiotensin 1-7, Saline solution
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Tucson, Arizona
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Optical Coherence Tomography
- Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
- Interventions
- Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
- Procedure · Diagnostic Test · Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Richmond, Virginia